|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D and Bray
F: GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide IARC
CancerBase No. 11. International Agency for Research on Cancer;
Lyon: 2013, http://globocan.iarc.fr.
Accessed September 3 , 2018.
|
|
2
|
Castro E, Mateo J, Olmos D and de Bono JS:
Targeting DNA repair: The role of PARP inhibition in the treatment
of castration-resistant prostate cancer. Cancer J. 22:353–356.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lord CJ and Ashworth A: PARP inhibitors:
Synthetic lethality in the clinic. Science. 355:1152–1158. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robinson D, Van Allen EM, Wu YM, Schultz
N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC,
Attard G, et al: Integrative clinical genomics of advanced prostate
cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network
Inc.: NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines): Prostate cancer (Version 4. 2018 8/15/18). NCCN; Fort
Washington, PA: 2018, https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Accessed September 3 , 2018.
|
|
6
|
Giri VN, Knudsen KE, Kelly WK, Abida W,
Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett
A, et al: Role of genetic testing for inherited prostate cancer
risk: Philadelphia Prostate Cancer Consensus Conference 2017. J
Clin Oncol. 36:414–424. 2018. View Article : Google Scholar :
|
|
7
|
Gillessen S, Attard G, Beer TM, Beltran H,
Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, et
al: Management of patients with advanced prostate cancer: The
report of the Advanced Prostate Cancer Consensus Conference APCCC
2017. Eur Urol. 73:178–211. 2018. View Article : Google Scholar
|
|
8
|
Higgins JPT and Green S: Cochrane handbook
for systematic reviews of interventions [Internet] The Cochrane
Collaboration, Version 5.1.0. updated March 2011. 2011, http://handbook.cochrane.org/.
Accessed November 22 , 2017.
|
|
9
|
Centre for Reviews and Dissemination
Systematic Reviews: CRD's guidance for undertaking reviews in
health care. University of York; York: 2017, http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm.
Accessed November 22 , 2017.
|
|
10
|
Munn Z, Moola S, Lisy K, Riitano D and
Tufanaru C: Methodological guidance for systematic reviews of
observational epidemiological studies reporting prevalence and
cumulative incidence data. Int J Evid-Based Healthc. 13:147–153.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ioannidis JPA: Why most published research
findings are false. PLoS Med. 2:e1242005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Button KS, Ioannidis JP, Mokrysz C, Nosek
BA, Flint J, Robinson ES and Munafò MR: Power failure: Why small
sample size undermines the reliability of neuroscience. Nat Rev
Neurosci. 14:365–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Timms KM, Cuzick J, Neff C, Reid J,
Solimeno C, Sangale Z, Pruss D, Gutin A, Lanchbury JS and Stone S:
The molecular landscape of genome instability in prostate cancer.
Proceedings of the European Society for Medical Oncology Congress;
Copenhagen. 2016, http://discovery.northernlight.com/document.php?datasource=PHE&docid=PE20161109050002300&context=WK%40northernlight.com"xrefwindow" href="https://doi.org/10.1093/annonc/mdw363.63" id="d7e1504" name="d7e1504" shape="rect">https://doi.org/10.1093/annonc/mdw363.63.
Accessed December 7 , 2017.
|
|
14
|
Jefferies M, Cox A, Clarke A and Kynaston
H: Targeted next-generation sequencing analysis of primary prostate
cancer identifies potential therapeutic targets. J Urol. 197(Suppl.
4): e594–e595. 2017. View Article : Google Scholar
|
|
15
|
Gourdin TS and Lilly MB: Genomic profiling
of metastatic prostate cancer through analysis of circulating tumor
DNA (ctDNA). J Clin Oncol. 34(Suppl 2): 1742016. View Article : Google Scholar
|
|
16
|
Pritchard CC, Morrissey C, Kumar A, Zhang
X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, et
al: Complex MSH2 and MSH6 mutations in hypermutated microsatellite
unstable advanced prostate cancer. Nat Commun. 5:49882014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abida W, Armenia J, Gopalan A, Brennan R,
Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, et al:
Prospective genomic profiling of prostate cancer across disease
states reveals germline and somatic alterations that may affect
clinical decision making. JCO Precis Oncol. 2017:1–16. 2017.
|
|
18
|
Abeshouse A, Ahn J, Akbani R, Ally A, Amin
S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A, et al:
Cancer Genome Atlas Research Network: The molecular taxonomy of
primary prostate cancer. Cell. 163:1011–1025. 2015. View Article : Google Scholar
|
|
19
|
Nicolosi PLW, Michalski ST, Freschi B,
O'Leary E, Quintana R, Wilson I, Powers MP and Sartor O: Need for
re-evaluation of current guidelines based on results from germline
genetic testing in prostate cancer. J Clin Oncol. 35(Suppl 15):
50092017. View Article : Google Scholar
|
|
20
|
Nelson P, Mateo J, Beltran H, De Sarkar N,
Elemento O, Rubin MA, Vinson JN, Filipenko J, Robinson DR,
Chinnaiyan AM, et al: Inherited mutations in DNA repair genes in
men with metastatic castration-resistant prostate cancer. J Clin
Oncol. 34(Suppl 15): 50092016. View Article : Google Scholar
|
|
21
|
Pritchard CC, Mateo J, Walsh MF, De Sarkar
N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R,
et al: Inherited DNA-repair gene mutations in men with metastatic
prostate cancer. N Engl J Med. 375:443–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Romero Laorden N, Lozano Mejorada R,
Piulats Rodriguez J, Vallespin E, Montesa A, Lorente Estelles D,
Villaguzman J, Grau G, Rodriquez-Vida A, Ibanez K, et al: 826P -
Prevalence and baseline clinico-pathological associations of
germline deleterious mutations in DNA repair genes (gmDDR) in a
metastatic castration resistant prostate cancer (mCRPC) prospective
spanish cohort (PROREPAIR-B study). Presented at European Society
for Medical Oncology (ESMO) 2017 Congress; 1-12 Sep 2017; Madrid:
Spain. https://cslide.ctimeetingtech.com/library/esmo/browse/search/2yZL#2Bb5p0SK
Accessed February 28 , 2018.
|
|
23
|
Struss WJ, Annala M, Warner EW, Beja K,
Vandekerkhove G, Wong A, Gleave M, Chi KN and Wyatt AW: Germline
DNA repair mutations in metastatic castration-resistant prostate
cancer: Therapy response and applicability of circulating tumor
DNA. J Clin Oncol. 35(Suppl 6): 1402017. View Article : Google Scholar
|
|
24
|
Lu C, Xie M, Wendl MC, Wang J, McLellan
MD, Leiserson MDM Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee
T, et al: Patterns and functional implications of rare germline
variants across 12 cancer types. Nat Commun. 6:100862015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Na R, Zheng SL, Han M, Yu H, Jiang D, Shah
S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, et al: Germline
mutations in ATM and BRCA1/2 distinguish risk for lethal and
indolent prostate cancer and are associated with early age at
death. Eur Urol. 71:740–747. 2017. View Article : Google Scholar :
|
|
26
|
Grasso CS, Wu YM, Robinson DR, Cao X,
Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC,
et al: The mutational landscape of lethal castration-resistant
prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manson-Bahr D, Ball R, Gundem G, Sethia K,
Mills R, Rochester M, Goody V, Anderson E, O'Meara S, Flather M, et
al: Mutation detection in formalin-fixed prostate cancer biopsies
taken at the time of diagnosis using next-generation DNA
sequencing. J Clin Pathol. 68:212–217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Evans JR, Zhao SG, Chang SL, Tomlins SA,
Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, et
al: Patient-level DNA damage and repair pathway profiles and
prognosis after prosta-tectomy for high-risk prostate cancer. JAMA
Oncol. 2:471–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patel VL, Busch E, D'Amico AV and Rebbeck
TR: BRCA2 mutations in prostate cancer assort into cluster regions.
Int J Radiat Oncol. 96:E569–E570. 2016. View Article : Google Scholar
|
|
30
|
Decker B, Karyadi DM, Davis BW, Karlins E,
Tillmans LS, Stanford JL, Thibodeau SN and Ostrander EA: Biallelic
BRCA2 mutations shape the somatic mutational landscape of
aggressive prostate tumors. Am J Hum Genet. 98:818–829. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Castro E, Goh CL, Olmos D, Leongamornlert
D, Saunders E, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K,
Guy M, et al: Correlation of germ-line BRCA2 mutations with
aggressive prostate cancer and outcome. J Clin Oncol. 29(Suppl 15):
15172011. View Article : Google Scholar
|
|
32
|
Leongamornlert D, Mahmud N, Tymrakiewicz
M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M,
O'Brien L, et al: UKGPCS Collaborators: Germline BRCA1 mutations
increase prostate cancer risk. Br J Cancer. 106:1697–1701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sonpavde G, Nagy RJ, Sartor AO, Pond GR,
Gourdin TS, Nandagopal L, Ledet EM, Agarwal N, Carroll E, Naik G,
et al: Circulating tumor (ct)-DNA alterations in metastatic
castration-resistant prostate cancer (mCRPC): Association with
outcomes and evolution with therapy. J Clin Oncol. 35(Suppl 6):
1492017. View Article : Google Scholar
|
|
34
|
Lara P, McPherson J, Heyer W, Hartmaier R,
DeVere White R, Ching J, Ali S and Dall'Era M: 827P - Comprehensive
char-acterization of BRCA1 and BRCA2 alterations in circulating
tumor DNA and tumor tissue in men with prostate cancer:
Implications for clinical care. Presented at European Society for
Medical Oncology (ESMO) 2017 Congress; 1-12 Sep 2017; Madrid:
Spain. 2017, https://cslide.ctimeetingtech.com/library/esmo/browse/search/2ape#2Bb5p0Vn.
Accessed February 28 , 2018.
|
|
35
|
Myers CE, Feldman R, Abbott BL, Reddy SK
and Castro M: Frequency of BRCA mutations and co-occurring
alterations in prostate cancer. J Clin Oncol. 34(Suppl 2): 2892016.
View Article : Google Scholar
|
|
36
|
Akbari MR, Wallis CJD, Toi A, Trachtenberg
J, Sun P, Narod SA and Nam RK: The impact of a BRCA2 mutation on
mortality from screen-detected prostate cancer. Br J Cancer.
111:1238–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maier C, Herkommer K, Luedeke M, Rinckleb
A, Schrader M and Vogel W: Subgroups of familial and aggressive
prostate cancer with considerable frequencies of BRCA2 mutations.
Prostate. 74:1444–1451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fontugne J, Ramazanoglu S, Knudsen K, De
Bono J, Feng F, Sboner A and Rubin M: DNA damage response genes in
prostate cancer: Development of a novel targeted sequencing
platform. Lab Invest. 95:220A–221A. 2015.
|
|
39
|
Nicolas E, Arora S, Zhou Y, Serebriiskii
IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL,
Ross EA, et al: Systematic evaluation of underlying defects in DNA
repair as an approach to case-only assessment of familial prostate
cancer. Oncotarget. 6:39614–39633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Armenia J, Wankowicz SAM, Liu D, Gao J,
Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I,
et al: PCF/SU2C International Prostate Cancer Dream Team: The long
tail of oncogenic drivers in prostate cancer. Nat Genet.
50:645–651. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Leongamornlert D, Saunders E, Dadaev T,
Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K,
Assiotis I, Barrowdale D, et al: UKGPCS Collaborators: Frequent
germline deleterious mutations in DNA repair genes in familial
prostate cancer cases are associated with advanced disease. Br J
Cancer. 110:1663–1672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hayano T, Matsui H, Nakaoka H, Ohtake N,
Hosomichi K, Suzuki K and Inoue I: Germline variants of prostate
cancer in Japanese families. PLoS One. 11:e01642332016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Isaacsson Velho P, Silberstein JL,
Markowski MC, Luo J, Lotan TL, Isaacs WB and Antonarakis ES:
Intraductal/ductal histology and lymphovascular invasion are
associated with germline DNA-repair gene mutations in prostate
cancer. Prostate. 78:401–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Quigley DA, Dang HX, Zhao SG, Lloyd P,
Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, et
al: Genomic hallmarks and structural variation in metastatic
prostate cancer. Cell. 174:758–769.e9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Marshall CH, Fu W, Wang H, Baras AS, Lotan
TL and Antonarakis ES: Prevalence of DNA repair gene mutations in
localized prostate cancer according to clinical and pathologic
features: Association of Gleason score and tumor stage. Prostate
Cancer Prostatic Dis. 22:59–65. 2019. View Article : Google Scholar :
|
|
46
|
Petrovics G, Ravindranath L, Chen Y, Ying
K, Ali A, Young D, McLeod D, Sesterhenn I, Rosner I, Dahut W, et
al: Higher frequency of germline BRCA1 and BRCA2 mutations in
African American prostate cancer. J Urol. 195(Suppl. 4): e5482016.
View Article : Google Scholar
|
|
47
|
Williams BJ, Jones E, Zhu XL, Steele MR,
Stephenson RA, Rohr LR and Brothman AR: Evidence for a tumor
suppressor gene distal to BRCA1 in prostate cancer. J Urol.
155:720–725. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao X, Zacharek A, Salkowski A, Grignon
DJ, Sakr W, Porter AT and Honn KV: Loss of heterozygosity of the
BRCA1 and other loci on chromosome 17q in human prostate cancer.
Cancer Res. 55:1002–1005. 1995.PubMed/NCBI
|
|
49
|
Hussain M, Daignault-Newton S, Twardowski
PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D,
Lonigro RJ, et al: Targeting androgen receptor and DNA repair in
metastatic castration-resistant prostate cancer: Results from NCI
9012. J Clin Oncol. 36:991–999. 2018. View Article : Google Scholar :
|
|
50
|
Annala M, Struss WJ, Warner EW, Beja K,
Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, et al:
Treatment outcomes and tumor loss of heterozygosity in germline DNA
repair-deficient prostate cancer. Eur Urol. 72:34–42. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cyll K, Ersvær E, Vlatkovic L, Pradhan M,
Kildal W, Avranden Kjær M, Kleppe A, Hveem TS, Carlsen B, Gill S,
et al: Tumour heterogeneity poses a significant challenge to cancer
biomarker research. Br J Cancer. 117:367–375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bedard PL, Hansen AR, Ratain MJ and Siu
LL: Tumour heterogeneity in the clinic. Nature. 501:355–364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stanta G and Bonin S: A practical approach
to tumor heterogeneity in clinical research and diagnostics.
Pathobiology. 85:7–17. 2018. View Article : Google Scholar
|
|
54
|
Simon RM, Paik S and Hayes DF: Use of
archived specimens in evaluation of prognostic and predictive
biomarkers. J Natl Cancer Inst. 101:1446–1452. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Moore HM, Kelly AB, Jewell SD, McShane LM,
Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield E, et
al: Biospecimen reporting for improved study quality (BRISQ). J
Proteome Res. 10:3429–3438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Little J, Higgins JP, Ioannidis JP, Moher
D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw
J, et al: STrengthening the REporting of Genetic Association
Studies: STrengthening the REporting of Genetic Association Studies
(STREGA): An extension of the STROBE statement. PLoS Med.
6:e222009. View Article : Google Scholar
|
|
57
|
Nam RK, Zhang WW, Jewett MA, Trachtenberg
J, Klotz LH, Emami M, Sugar L, Sweet J, Toi A and Narod SA: The use
of genetic markers to determine risk for prostate cancer at
prostate biopsy. Clin Cancer Res. 11:8391–8397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Näslund-Koch C, Nordestgaard BG and
Bojesen SE: Increased risk for other cancers in addition to breast
cancer for CHEK2*1100delC heterozygotes estimated from
the Copenhagen General Population Study. J Clin Oncol.
34:1208–1216. 2016. View Article : Google Scholar
|
|
59
|
Maier C, Wiest I, Luedeke M, Surowy H,
Rinckleb A, Herkommer K, Kuefer R and Vogel W: BRCA2 mutation
analysis in familial and early onset prostate cancer. Med Genetik.
22:97–98. 2010.
|
|
60
|
Vazina A, Baniel J, Yaacobi Y, Shtriker A,
Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T,
et al: The rate of the founder Jewish mutations in BRCA1 and BRCA2
in prostate cancer patients in Israel. Br J Cancer. 83:463–466.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tanaka Y, Zaman MS, Majid S, Liu J,
Kawakami K, Shiina H, Tokizane T, Dahiya AV, Sen S and Nakajima K:
Polymorphisms of MLH1 in benign prostatic hyperplasia and sporadic
prostate cancer. Biochem Biophys Res Commun. 383:440–444. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Uchida T, Wang C, Sato T, Gao J, Takashima
R, Irie A, Ohori M and Koshiba K: BRCA1 gene mutation and loss of
heterozygosity on chromosome 17q21 in primary prostate cancer. Int
J Cancer. 84:19–23. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cendón Flórez Y, Nombela Blanco P, Medina
A, Romero Laorden N, Puente J, López Casas P, Gutierrez Pecharromán
A, Sanchez-Escribano R, Magraner L, Gallardo Diaz E, et al: 1660P -
ATM role in prostate cancer (PrCa) progression and survival.
Presented at European Society for Medical Oncology (ESMO) 2017
Congress; 1-12 Sep 2017; Madrid: Spain. https://cslide.ctimeetingtech.com/library/esmo/browse/search/2yZz.
Accessed February 28 , 2018.
|
|
64
|
Centro Nacional de Investigaciones
Oncologicas CARLOS III: Prospective multicentre cohort study
PROREPAIR-B (mCRPC) NCT03075735. WHO International Clinical Trials
Registry Platform (ICTRP) [Internet] Geneva: World Health
Organization (WHO); 2017, https://clinicaltrials.gov/show/NCT03075735.
Accessed December 12 , 2017.
|
|
65
|
Angèle S, Falconer A, Edwards SM, Dörk T,
Bremer M, Moullan N, Chapot B, Muir K, Houlston R, Norman AR, et
al: ATM polymorphisms as risk factors for prostate cancer
development. Br J Cancer. 91:783–787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dawson NA, Heath EI, Feldman R, Reddy SK,
Spetzler D, Poste GH and Raghavan D: Use of panomic assessment to
reveal DNA repair alterations and to predict potential therapeutic
response to taxaneplatinum combination therapy in prostate cancer.
J Clin Oncol. 34(Suppl 15): pp. 50402016, View Article : Google Scholar
|
|
67
|
Xia S, Kohli M, Du M, Dittmar RL, Lee A,
Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, et al: Plasma genetic
and genomic abnormalities predict treatment response and clinical
outcome in advanced prostate cancer. Oncotarget. 6:16411–16421.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Abida W, Curtis KR, Taylor BS, Arcila ME,
Brennan R, Danila DC, Rathkopf DE, Morris MJ, Slovin SF, Solit DB,
et al: Genomic characterization of primary and metastatic prostate
cancer (PC) using a targeted next-generation sequencing assay. J
Clin Oncol. 33(Suppl 15): 50622015. View Article : Google Scholar
|
|
69
|
Abida W, Walsh MF, Armenia J, Vijai J,
Gopalan A, Brennan R, Curtis K, Arcila M, Danila D, Arnold A, et
al: Next generation sequencing of prostate cancer reveals germline
and somatic alterations detected at diagnosis and at metastasis
that may impact clinical decision making. Cancer Res.
76:LB-0702016.
|
|
70
|
Abida W, Brennan R, Armenia J, Curtis KR,
Gopalan A, Arcila ME, Danila DC, Rathkopf DE, Morris MJ, Slovin SF,
et al: Genomic characterization of primary and metastatic prostate
cancer (PC) using a targeted next-generation sequencing assay. J
Clin Oncol. 34(Suppl 2): 2542016. View Article : Google Scholar
|
|
71
|
Cheng ML, Abida W, Rathkopf DE, Arcila ME,
Barron D, Autio KA, Zehir A, Danila DC, Morris MJ, Gopalan A, et
al: Next-generation sequencing (NGS) of tissue and cell free DNA
(cfDNA) to identify somatic and germline alterations in advanced
prostate cancer. J Clin Oncol. 35(Suppl 15): 15102017. View Article : Google Scholar
|
|
72
|
Feldman RA, Dan Basu G, Xiu J, Arguello D,
Millis SZ, Bender R, Gatalica Z, Paul L and Myers CE: Molecular
profiling of advanced refractory prostate cancer. J Clin Oncol.
32(Suppl 4): 1072014. View Article : Google Scholar
|
|
73
|
Palapattu GS, Cani AK, Huang J, Hovelson
DH, Lu D, Margolis D, Natarajan S, Mehra R, Montgomery JS, Morgan
TM, et al: Progression of low-to high-grade prostate cancer:
Molecular profiling of tissue obtained by serial targeted biopsy. J
Clin Oncol. 33(Suppl 15): 50172015. View Article : Google Scholar
|
|
74
|
Browning RE IV, Li H, Shinohara ET, Cai Q,
Chen H, Courtney R, Cao C, Zheng W and Lu B: ATM polymorphism
IVS62+60G>A is not associated with disease aggressiveness in
prostate cancer. Urology. 67:1320–1323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Patel V, Busch E, D'Amico A and Rebbeck T:
BRCA2 mutations in prostate cancer assort into cluster regions. J
Radiat Oncol. 6:229–230. 2017.
|
|
76
|
Wu X, Dong X, Liu W and Chen J:
Characterization of CHEK2 mutations in prostate cancer. Hum Mutat.
27:742–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Dall'Era M, Glass A, Lara P, Hartmaier R,
DeVere White R and McPherson J: Frequency of DNA repair gene
mutations in localized and metastatic prostate cancer. J Clin
Oncol. 35(Suppl 6): 102017. View Article : Google Scholar
|
|
78
|
Glass A, Lara P, Hartmaier R, DeVere White
R, McPherson J and Dall'Era M: Frequency of DNA repair gene
mutations in localized and metastatic prostate cancer. J Urol.
197(Suppl 4): e56–e57. 2017. View Article : Google Scholar
|
|
79
|
Beltran H, Eng K, Mosquera JM, Sigaras A,
Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, et
al: Whole-exome sequencing of metastatic cancer and biomarkers of
treatment response. JAMA Oncol. 1:466–474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Beltran H, Sboner A, Mosquera JM, Rickman
D, Eng K, Prandi D, Kossai M, Faltas B, Pauli C, Fontugne J, et al:
Precision medicine program for whole-exome sequencing (WES)
provides new insight on platinum sensitivity in advanced prostate
cancer (PCa). J Clin Oncol. 33(Suppl 7): 1582015. View Article : Google Scholar
|
|
81
|
Beltran H, Yelensky R, Frampton GM, Park
K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus
DM, et al: Targeted next-generation sequencing of advanced prostate
cancer identifies potential therapeutic targets and disease
heterogeneity. Eur Urol. 63:920–926. 2013. View Article : Google Scholar :
|
|
82
|
Gambhira R, Ledet EM, Dotiwala A, Mandal D
and Sartor AO: Copy number variations in AR-associated and DNA
repair genes from plasma cell-free DNA of metastatic CRPC patients.
J Clin Oncol. 34(Suppl 2): 2812016. View Article : Google Scholar
|
|
83
|
Daniel S, Gornstein E, Frampton GM, Sun J,
Morley S, Heilmann A, Reddy P, Chung J, Suh J, Ramkissoon S, et al:
BRCA1/2 reversion mutations in prostate cancer identified from
clinical tissue and liquid biopsy samples. J Clin Oncol. 35(Suppl
15): 50242017. View Article : Google Scholar
|
|
84
|
Robbins CM, Tembe WA, Baker A, Sinari S,
Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M,
Long J, Chinnaiyan A, et al: Copy number and targeted mutational
analysis reveals novel somatic events in metastatic prostate
tumors. Genome Res. 21:47–55. 2011. View Article : Google Scholar :
|
|
85
|
Hebbring SJ, Fredriksson H, White KA,
Maier C, Ewing C, McDonnell SK, Jacobsen SJ, Cerhan J, Schaid DJ,
Ikonen T, et al: Role of the Nijmegen breakage syndrome 1 gene in
familial and sporadic prostate cancer. Cancer Epidemiol Biomarkers
Prev. 15:935–938. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Baca SC, Prandi D, Lawrence MS, Mosquera
JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi
M, et al: Punctuated evolution of prostate cancer genomes. Cell.
153:666–677. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu Z, Zhou M, Lepor H, Zoino R, Rajoria G
and Klimek S: Mutational analysis of prostate cancer using next
generation cancer hotspot panel. Lab Invest. 96:246A–247A.
2016.
|
|
88
|
Cheng Y, Thorne H, Bolton D, Clouston D,
Willems A, Li J, Niedermeyer E, Fox S and Mitchell G: Altered
significance of D'Amico risk assessment in BRCA2 positive vs
negative patients from high risk breast cancer families. J Urol.
185(Suppl. 4): e622011. View Article : Google Scholar
|
|
89
|
Gayther SA, de Foy KA, Harrington P,
Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A,
Dearnaley DP, Easton DF, et al: The Cancer Research
Campaign/British Prostate Group United Kingdom Familial Prostate
Cancer Study Collaborators: The frequency of germ-line mutations in
the breast cancer predisposition genes BRCA1 and BRCA2 in familial
prostate cancer. Cancer Res. 60:4513–4518. 2000.PubMed/NCBI
|
|
90
|
Zuhlke KA, Johnson AM, Okoth LA, Stoffel
EM, Robbins CM, Tembe WA, Salinas CA, Zheng SL, Xu J, Carpten JD,
et al: Identification of a novel NBN truncating mutation in a
family with hereditary prostate cancer. Fam Cancer. 11:595–600.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
LaDuca H, Espenschied C, Dolinsky JS,
Smith LP, Fulk K, Pronold M, Horton C, Couch FJ and Davis BT:
Hereditary cancer panel results identify gaps in knowledge of
cancer risks and limitations in current guidelines. In: Presented
at the American Society of Human Genetics Annual Meeting; 17 - 21
Oct , 2017; Orlando: United States. 2017
|
|
92
|
Ledet EM, Ernst EM, Schiff J, Lin S, Lewis
BE and Sartor AO: Germline variants and family history in caucasian
and African-American prostate cancer. J Clin Oncol. 35(Suppl 15):
pp. e165482017, View Article : Google Scholar
|
|
93
|
Lin S, Ledet EM, Schiff J, Ernst EM,
Garvey CE, Lewis BE and Sartor O: Inherited pathologic mutations
and family history in patients with prostate cancer. J Clin Oncol.
35(Suppl 6): pp. 1852017, View Article : Google Scholar
|
|
94
|
Marshall M, Tully D, Susswein L, Theobald
K, Murphy P and Klein R: Panel testing in men with prostate cancer
meeting NCCN genetic testing criteria (AB2017-59). J Natl Compr
Canc Netw. 15:e15–e16. 2017.
|
|
95
|
Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi
DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA,
et al: Identification and characterization of novel SNPs in CHEK2
in Ashkenazi Jewish men with prostate cancer. Cancer Lett.
270:173–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Hamel N, Kotar K and Foulkes WD: Founder
mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish
men with prostate cancer. BMC Med Genet. 4:72003. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Damaraju S, Murray D, Dufour J, Carandang
D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, et
al: Association of DNA repair and steroid metabolism gene
polymorphisms with clinical late toxicity in patients treated with
conformal radiotherapy for prostate cancer. Clin Cancer Res.
12:2545–2554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Meyer A, Wilhelm B, Dörk T, Bremer M,
Baumann R, Karstens JH and Machtens S: ATM missense variant P1054R
predisposes to prostate cancer. Radiother Oncol. 83:283–288. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Nientiedt C, Heller M, Endris V, Volckmar
AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher
P, Sültmann H, et al: Mutations in BRCA2 and taxane resistance in
prostate cancer. Sci Rep. 7:45742017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hubert A, Peretz T, Manor O, Kaduri L,
Wienberg N, Lerer I, Sagi M and Abeliovich D: The Jewish Ashkenazi
founder mutations in the BRCA1/BRCA2 genes are not found at an
increased frequency in Ashkenazi patients with prostate cancer. Am
J Hum Genet. 65:921–924. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
101
|
Giusti RM, Rutter JL, Duray PH, Freedman
LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B,
Fischbein A, Gruber SB, et al: A twofold increase in BRCA mutation
related prostate cancer among Ashkenazi Israelis is not associated
with distinctive histopathology. J Med Genet. 40:787–792. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kote-Jarai Z, Leongamornlert D, Saunders
E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L,
Sawyer E, et al: UKGPCS Collaborators: BRCA2 is a moderate
penetrance gene contributing to young-onset prostate cancer:
Implications for genetic testing in prostate cancer patients. Br J
Cancer. 105:1230–1234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi
R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, et
al: Cancer Research UK/Bristish Prostate Group UK Familial Prostate
Cancer Study Collaborators; British Association of Urological
Surgeons Section of Oncology: Two percent of men with early-onset
prostate cancer harbor germline mutations in the BRCA2 gene. Am J
Hum Genet. 72:1–12. 2003. View
Article : Google Scholar
|
|
104
|
Agalliu I, Karlins E, Kwon EM, Iwasaki LM,
Diamond A, Ostrander EA and Stanford JL: Rare germline mutations in
the BRCA2 gene are associated with early-onset prostate cancer. Br
J Cancer. 97:826–831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gallagher DJ, Cronin AM, Milowsky MI,
Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K and Robson
ME: Germline BRCA mutation does not prevent response to
taxane-based therapy for the treatment of castration-resistant
prostate cancer. BJU Int. 109:713–719. 2012. View Article : Google Scholar
|
|
106
|
Agalliu I, Gern R, Leanza S and Burk RD:
Associations of high-grade prostate cancer with BRCA1 and BRCA2
founder mutations. Clin Cancer Res. 15:1112–1120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kirchhoff T, Kauff ND, Mitra N, Nafa K,
Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, et
al: BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
Clin Cancer Res. 10:2918–2921. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lehrer S, Fodor F, Stock RG, Stone NN, Eng
C, Song HK and McGovern M: Absence of 185delAG mutation of the
BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi
Jewish men with prostate cancer. Br J Cancer. 78:771–773. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cesaretti JA, Stock RG, Atencio DP, Peters
SA, Peters CA, Burri RJ, Stone NN and Rosenstein BS: A genetically
determined dose-volume histogram predicts for rectal bleeding among
patients treated with prostate brachytherapy. Int J Radiat Oncol
Biol Phys. 68:1410–1416. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhu Y, Marshall D, Garrett-Mayer E, Zhou D
and Jenrette J: Association between urinary morbidity/erectile
dysfunction induced by radiotherapy and SNPs of
radiosensitivity-relevant genes in prostate cancer patients. Clin
Chem. 56:A902010.
|
|
111
|
Pomerantz MM, Spisák S, Jia L, Cronin AM,
Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT,
et al: The association between germline BRCA2 variants and
sensitivity to platinum-based chemotherapy among men with
metastatic prostate cancer. Cancer. 123:3532–3539. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hart SN, Ellingson MS, Schahl K, Vedell
PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE,
Wang L, et al: Determining the frequency of pathogenic germline
variants from exome sequencing in patients with castrate-resistant
prostate cancer. BMJ Open. 6:e0103322016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Antonarakis ES, Lu C, Luber B, Liang C,
Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, et al:
Germline DNA-repair gene mutations and outcomes in men with
metastatic castration-resistant prostate cancer receiving
first-line abiraterone and enzalutamide. Eur Urol. 74:218–225.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Nastiuk KL, Mansukhani M, Terry MB,
Kularatne P, Rubin MA, Melamed J, Gammon MD, Ittmann M and
Krolewski JJ: Common mutations in BRCA1 and BRCA2 do not contribute
to early prostate cancer in Jewish men. Prostate. 40:172–177. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Schweizer MT, Cheng HH, Tretiakova MS,
Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu
EY, Montgomery B, et al: Mismatch repair deficiency may be common
in ductal adenocarcinoma of the prostate. Oncotarget.
7:82504–82510. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Stephens PJ, Gay LM, Ali SM,
Hoffman-Censits JH, Elvin JA, Vergilio JA, Suh J, Mian B, Fisher
HAG, Nazeer T, et al: Comprehensive genomic profiling of
neuroendocrine carcinoma of the prostate. J Clin Oncol. 34(Suppl
15): 1872016. View Article : Google Scholar
|
